Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.57 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.56 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CD74 | P04233 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9454035 | 0.89 | CYP4F2 (0.58) | CYP4F2CYP4A11HDAC1RAB9ASMN1; SMN2 | |
| SCHEMBL914873 | 0.89 | LOXL2 (0.57) | LOXL2CYP4F2CYP4A11SLC7A5FOLH1 | |
| SCHEMBL3475567 | 0.87 | LOXL2 (0.62) | LOXL2CYP4F2CYP4A11SLC7A5FOLH1 | |
| SCHEMBL8669463 | 0.85 | HDAC1 (0.50) | LOXL2CYP4F2CYP4A11HDAC1MRGPRX4 | |
| SCHEMBL915153 | 0.85 | MRGPRX4 (0.54) | HDAC1FOLH1MRGPRX4RAB9ASMN1; SMN2 | |
| SCHEMBL915654 | 0.85 | KDM4E (0.46) | LOXL2CYP4F2CYP4A11HDAC1SLC7A5 | |
| SCHEMBL23684777 | 0.85 | SLC7A5 (0.53) | LOXL2CYP4F2CYP4A11HDAC1SLC7A5 | |
| SCHEMBL30260202 | 0.85 | SLC7A5 (0.53) | LOXL2CYP4F2CYP4A11HDAC1SLC7A5 | |
| SCHEMBL27233594 | 0.83 | FAAH (0.48) | HDAC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL10584686 | 0.83 | RAB9A (0.46) | LOXL2CYP4F2CYP4A11HDAC1SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313546-A1 | NUCLEIC ACID BINDERS | UNIVERSITY OF STRATHCLYDE (GB) | 2025-10-09 | — | — | US | disclosed |
| US-20250298333-A1 | POLYESTER RESIN COMPOSITION, ELECTROSTATIC CHARGE IMAGE DEVELOPING TONER, DEVELOPER, AND IMAGE FORMING METHOD | Konica Minolta, Inc. (JP) | 2025-09-25 | — | — | US | disclosed |
| EP-4522588-A1 | NUCLEIC ACID BINDERS | University of Strathclyde (GB) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023218194-A1 | NUCLEIC ACID BINDERS | UNIVERSITY OF STRATHCLYDE (GB) | 2023-11-16 | — | — | WO | disclosed |
| CN-110878052-B | FXR agonist-containing compound and preparation method and application thereof | 山东大学 | 2021-05-07 | — | — | CN | disclosed |
| CN-110878052-A | FXR agonist-containing compound and preparation method and application thereof | 山东大学 | 2020-03-13 | — | — | CN | disclosed |
| CN-105884758-A | Tricyclic compound and application thereof to drugs | 广东东阳光药业有限公司 | 2016-08-24 | — | — | CN | disclosed |
| CN-104513213-A | Fxr agonist | KBP BIOSCIENCES CO LTD | 2015-04-15 | — | — | CN | disclosed |
| US-8952042-B2 | FXR (NR1H4) binding and activity modulating compounds | PHENEX PHARMACEUTICALS AG (DE) | 2015-02-10 | — | — | US | disclosed |
| US-8952042-B2 | FXR (NR1H4) binding and activity modulating compounds | PHENEX PHARMACEUTICALS AG (DE) | 2015-02-10 | — | — | US | disclosed |
| US-20080249280-A1 | Process for Producing Polyester, Polyester Produced Using Said Process, and Polyester Molded Product | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-10-09 | — | — | US | disclosed |
| CN-101263175-A | Polyester, process for production of polyester, and polyester molded article | TOYO BOSEKI (JP) | 2008-09-10 | — | — | CN | disclosed |
| CN-101208371-A | Method for preparing polyester and polyester manufactured by the method as well as polyester formed body | TOYO BOSEKI (JP) | 2008-06-25 | — | — | CN | disclosed |
| EP-1932867-A1 | POLYESTER, PROCESS FOR PRODUCTION OF POLYESTER, AND POLYESTER MOLDED ARTICLE | Toyo Boseki Kabushiki Kasisha (JP) | 2008-06-18 | — | — | EP | disclosed |
| WO-2008038018-A1 | NOVEL MINOR GROOVE BINDERS | UNIVERSITY OF STRATHCLYDE (GB) | 2008-04-03 | — | — | WO | disclosed |
| WO-2007140174-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| EP-1842868-A1 | PROCESS FOR PRODUCING POLYESTER, POLYESTER PRODUCED USING SAID PROCESS, AND POLYESTER MOLDED PRODUCT | Toyo Boseki Kabushiki Kasisha (JP) | 2007-10-10 | — | — | EP | disclosed |
| US-20010037025-A1 | New compounds, their preparation and use | MURRAY ANTHONY (DK) | 2001-11-01 | — | — | US | disclosed |
| EP-1077919-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058486-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037025-A1 | New compounds, their preparation and use | GPR119, SLC5A1, SLC5A2 | LOXL2 4024/4885CYP4F2 849/4885CYP4A11 180/4885 |
| US-20250313546-A1 | NUCLEIC ACID BINDERS | ZFR, NSUN3, POLI | LOXL2 4699/4885CYP4F2 4809/4885CYP4A11 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.